advertisement
Abstract #108064 Published in IGR 23-4
Topical Diacerein Decreases Skin and Splenic CD11c Dendritic Cells in Psoriasis
Brunner SM; Ramspacher A; Rieser C; Leitner J; Heil H; Ablinger M; Tevini J; Wimmer M; Koller A; Piñón Hofbauer J; Felder TK; Bauer JW; Kofler B; Lang R; Wally VInternational journal of molecular sciences 2023; 24:
Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.
Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
Full article